Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Nov 2016
transgene
Joint bookrunner
€ 46.4 million
Rights issue

Transgene

Transgene focuses on the development of targeted immunotherapies for the treatment of cancer and infectious diseases

  • Rights issue amounting to €46.4m.
  • Proceeds will be used to fund its clinical development plan with the launch of seven clinical trials.
  • Kempen & Co acted as Joint Bookrunner in the transaction.

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer